Loading clinical trials...
Loading clinical trials...
This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Forest Laboratories
Collaborators
NCT07592689 · Major Depressive Disorder
NCT07539805 · Major Depressive Disorder (MDD), Probiotic Intervention
NCT07645157 · Major Depressive Disorder (MDD), Probiotic Intervention
NCT07642882 · Fibromyalgia, Depression - Major Depressive Disorder, and more
NCT07621237 · Major Depressive Episode (MDE), Major Depressive Disorder (MDD), and more
Forest Investigative Site 040
Phoenix, Arizona
Forest Investigative Site 038
Scottsdale, Arizona
Forest Investigative Site
Arcadia, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions